人福醫藥(600079.SH):定增併購案通過股東大會審核
8月26日晚間,人福醫藥(600079.SH)對外發布公告稱,在當日舉行的股東大會上,公司發行股份購買資產並募集配套資金暨關聯交易議案獲股東大會一致審議通過。本次交易完成後,人福醫藥集團將持有宜昌人福80%股權,同時還將獲得控股股東當代集團募集的配套資金近10億元。
早在8月10日,人福醫藥集團發佈公告稱,上市公司擬通過發行股份的方式,向自然人李傑、陳小清、徐華斌購買其合計持有的宜昌人福13%股權。本次交易完成前,上市公司持有宜昌人福67%股權。
據瞭解,宜昌人福是國家麻醉藥品定點研發生產企業、國家重點高新技術企業。本次交易前,宜昌人福即為上市公司人福醫藥的控股子公司。本次交易為上市公司收購控股子公司宜昌人福少數股東權益,交易前後上市公司的主營業務範圍不會發生變化。
人福醫藥集團相關負責人介紹,本次收購是集團實施“歸核化”戰略,聚焦核心業務的重要舉措,有利於集中資源發展既定專業細分領域,推進業務聚焦與資產優化,有利於公司優化整合資源配置,提升上市公司的決策效率和整體管理效率,確保資源和技術的有效整合,提升上市公司整體價值。
據介紹,此次向控股股東當代集團募集的配套資金扣除相關中介機構費用及税費後,將用於宜昌人福“小容量注射製劑國際標準生產基地”項目建設及補充上市公司流動資金。
若本次交易非公開發行股份募集配套資金成功實施,將進一步優化上市公司資產結構;伴隨宜昌人福“小容量注射製劑國際標準生產基地”項目建成達產,上市公司盈利水平將得到進一步提升。人福醫藥集團相關負責人表示。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.